reduce worker productivity and child intellectual growth-and ultimately impair India's economy [6] -these diseases could become a focal point for such discussions.
The good news is that in recent years India has made important progress towards NTD control and elimination. WHO estimates that in 2015, approximately three-quarters of the more than 200 million Indian children that require deworming for their intestinal helminth infections received mass treatment [7] . India is also achieving a similar level of mass treatment coverage for almost 400 million people who are at risk for LF [8] , while for years the nation has been committed to multidrug therapy for leprosy (together with rifampicin post-exposure prophylaxis) [9, 10] , with such measures resulting in important public health gains. This level of mass drug administration needs to continue or expand in order to reach 100 percent of India's at-risk or infected population.
Additional opportunities exist to aid India's progress against many other NTDs, especially vector-borne diseases such as leishmaniasis, dengue, and other arbovirus infections. For example, India hosts a sophisticated and extensive network of biotechnology organizations and private companies capable of developing next-generation vaccines, drugs, and diagnostics. India has the capacity to become a leader in producing next-generation NTD technologies, which could include new leishmaniasis and dengue vaccines and other technologies [11, 12] . To achieve this goal, we'll need new partnerships between India's important and mostly private for-profit biotechs and its research universities. One such example is a dengue vaccine partnership between the International Centre for Genetic Engineering and Biotechnology (ICGEB) and Sun Pharma [13] . Together with increased access to these new technologies, a new vision for public-private partnerships would further reduce its NTD burden and indirectly promote economic development.
Presumably due in part to the fact that new NTD technologies are not considered profitable, India has not yet fully organized and directed its powerful biotechnology engine for building tools to combat its autochthonous NTDs. If this dynamic could change, it could [4] produce one of India's greatest contributions to global health and development [11] . NTD biotechnology for India and the South Asian region should become an important priority for PM Modi's government. During the 1970s India became a nuclear power. Some 40 years later, the world's largest democracy now has the opportunity to again flex its scientific and technical muscle to develop cutting-edge NTD technologies.
